The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Does Statin Use Have A Disease Modifying Effect In Symptomatic Knee Osteoarthritis?
Funder
National Health and Medical Research Council
Funding Amount
$133,194.00
Summary
Osteoarthritis (OA) is a major cause of knee pain and disability. Treatments are limited to reducing pain and improving function: no therapy slows disease progression, with symptomatic end-stage OA treated by knee replacement. Statins, a drug class used to lower cholesterol levels, may affect the structural progression in knee OA. We propose a randomised controlled trial to see if statin use slows the progression of knee OA, which would delay or prevent the need for joint replacement.
Does Statin Use Have A Disease Modifying Effect In Symptomatic Knee Osteoarthritis? A Multicentre Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,002,987.00
Summary
Osteoarthritis (OA) is a major cause of knee pain and disability. Treatments are limited to reducing pain and improving function: no therapy slows disease progression, with symptomatic end-stage OA treated by knee replacement. Statins, a drug class used to lower cholesterol levels, may affect the structural progression in knee OA. We propose a randomised controlled trial to see if statin use slows the progression of knee OA, which would delay or prevent the need for joint replacement.
Does Metformin Have A Disease Modifying Effect In Symptomatic Knee Osteoarthritis? A Multicentre Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Osteoarthritis(OA) is a major contributor to this disease burden. Currently, there is no therapy that slows disease progression. Metformin may affect OA progression via multiple pathways that address the pathogenesis of knee OA, including weight loss, glucose- and lipid-lowering, and anti-inflammation. This will be the world first randomised, double-blind controlled trial, to assess the effect of metformin, compared with placebo, on knee OA-related structural and clinical outcomes